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212Disease-speciﬁc guidelines for reporting adverse
events for peripheral vascular medical devices
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Raghvinder P. S. Gambhir, MD,e and Michael A. Ricci, MD,f New York, NY; Phoenix, Ariz; Houston, Tex;
London, Ontario, Canada; Delhi, India; and Lewiston, MeThis reporting standards document has been created in
two parts. Part One summarized existing multinational
governmental and nongovernmental guidelines and regula-
tions for reporting adverse events that occur with the use of
medical devices for peripheral vascular interventions.1
Other important components required for the safe and
proper conduct of a clinical trial evaluating vascular devices
were also summarized. The aim of the current document is
the same: to achieve greater reporting consistency between
clinicians, investigators, specialties, institutions, and investi-
gational studies.
In Part Two, the reporting of adverse events is orga-
nized by disease process. Formal guidelines were not spec-
iﬁed in Part One and deﬁnitions were in large part general.
Rather than the general suggestions and deﬁnitions
included in Part One, the recommendations in Part Two
are broadly grouped by vascular disease system: arterial
and venous. Within each system, recommendations are
included speciﬁc to an individual disease process, for
example, carotid stenosis, aortic aneurysms, and lower ex-
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://dx.doi.org/10.1016/j.jvs.2014.04.061The guidelines in this document were created by
consensus agreement of the authors with oversight provided
by members of the Society for Vascular Surgery (SVS)
Document Oversight Committee. Due consideration of
the existing SVS reporting standards documents for many
disease entities was taken; overlap and inconsistencies have
been minimized wherever possible. Whereas the reporting
recommendations and guidelines contained herein were
developed to be enduring, it is evident that they represent
nothing more than a snapshot in time. Newer technologies
will require newer standards and guidelines, but it is hoped
that this document will provide a basis for subsequent revi-
sions that will be necessary over time, by the nature of the
continual, progressive advancement in medical science.
GENERAL GUIDELINES
The general principles for reporting of adverse events
after use of a medical device were described in Part One
of this document set. There are certain deﬁnitions for
which reporting harmonization is of sufﬁcient importance
that deﬁnitions are best articulated as guidelines. The deﬁ-
nition of the term adverse event formed a basis for all other
deﬁnitions, including serious adverse events and unantici-
pated adverse device effects. When present, differences in
the deﬁnitions between the regulatory agencies of different
countries were identiﬁed and described.
In reporting of adverse events, it is important to pre-
cisely delineate the device and the procedure under study,
an issue that seems axiomatic but one that is not always
obvious. For instance, if the study device is a new angio-
plasty balloon, complications related to the guidewire or
sheath would be procedure related and not device related.
Use of the term index procedure was introduced and
encouraged to specify the time point of initial device use,
a time point on which many deﬁnitions are based. For
instance, assignment of causality or “relatedness” of an
event to the device or to the procedure is linked to when
the event occurred in relation to the index procedure.
Last, a priori enumeration of expected adverse events for
each device, even those events that occur at relatively low
frequency, forms a foundation for classifying an untoward
occurrence as “unanticipated,” a classiﬁcation that carries
Table I. Procedure and device relatedness after device
use in the arterial system
Device
Relatedness
Procedure Device
Carotid stent
Ischemic strokea X X
Hemorrhagic stroke X
MI X
Hypotension/hypertension X
Iatrogenic iliac artery injury Xb
Aortic endograft
Type I endoleak X
Type II endoleak X
Type III endoleak X
Type IV endoleak X
Migration Xc
Graft limb occlusion X
Iliac artery injury X
Endograft infection X
MI X
Renal failure X
Paraplegia X
Bowel ischemia X
Peripheral bypass graft
Graft occlusion X
Graft infection X
Wound infection X
MI X
Perigraft seroma X
Lymphocele/lymphorrhea X
Peripheral stent
Stent occlusion X
Stent fracture Xd
Distal embolization X
Arterial rupture Xe
MI, Myocardial infarction.
The assignment of relatedness is included as a guide; differences will arise on
the basis of individual clinical scenarios.
aIschemic strokes occurring during or after stent introduction and deploy-
ment would usually be classiﬁed as device related, whereas events that occur
earlier in the procedure would usually be procedure related.
bAn iliac artery injury occurring during placement of a sheath to deliver a
carotid stent is device related with respect to the sheath but procedure
related with respect to the stent.
cIf migration is thought to be a result of continued dilation of the aortic
neck, irrespective of the device, the event could be argued to be procedure
and not device related. Others may take the position that a perfect device
would adapt to continued neck enlargement without migrating.
dLike type II endoleaks after endovascular aneurysm repair, stent fracture
may not be associated with a discernible event of immediate clinical
consequence. The observation that stent thrombosis has been reported to
be associated with stent fracture and that, as designed, stents should
maintain integrity argues for classifying fractures as device-related adverse
events.
eIn many cases, rupture of the artery is related to overdilation during post-
stent angioplasty. As such, these events would not be device related. The
event would be device related if rupture occurred as a direct result of the
device or its components.
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to the prior document for these deﬁnitions; for the most
part, they are not repeated herein.1
The assignment of causality to an event is important in
reporting the results for any medical device: whether an
event is related to the device itself, whether it occurred as
a result of the procedure, or whether it was unrelated to
either (Table I). In this regard, a device should be consid-
ered to include the device itself as well as the intrinsic com-
ponents used during device deployment. Complications
associated with failure of a device to deploy in accordance
with its design are considered to be device related. As
well, a complication often overlooked after endovascular
interventions is radiation injury from excessive or inadver-
tent exposure. Radiation injury should be classiﬁed as a
procedure-related adverse event.
Events that occur before the use of the study device are
considered to be “preexisting conditions” and are unre-
lated to the use of the device unless the condition worsens
in severity after the index procedure. By deﬁnition, events
occurring within 30 days of an index procedure or any sec-
ondary intervention are at least procedure related; in other
words, they are by default procedure related unless they are
device related. Whenever possible, events should not be
classiﬁed as both procedure related and device related.
Where there is ambiguity, the latter trumps the former.
The assignment of device or procedure relatedness can
be debatable for events occurring from technical errors or
failure to follow a device’s instructions for use (IFU). Ex-
amples include an iatrogenic arteriovenous ﬁstula from
improper placement of a central venous catheter (technical
error) and migration of an aortic endograft deployed in a
patient with 75-degree aortic neck angulation (failure to
follow the IFU). It is recommended that technical errors
be classiﬁed as procedure-related events. By contrast, the
restricted indications in a device’s IFU reﬂect the narrow
eligibility criteria in the initial clinical trials designed to
obtain regulatory clearance or approval.2 Clinicians may
use a device outside of the IFU in the best interest of an
individual patient. Unless such events are the result of
obvious operator error, it is recommended that complica-
tions occurring when a device is used outside of the IFU
be classiﬁed as device-related events. That said, it is useful
to know whether an event occurred within or outside of
the IFU, particularly for subsequent data analysis. It is rec-
ommended that such complications be subclassiﬁed as “de-
vice-related, non-IFU use” adverse events.
Classiﬁcation of an event by its temporal relationship to
the index procedure can be of value. Various reporting
standards documents have deﬁned different thresholds for
early, midterm, and late events. Whereas this reporting
standards document has striven to avoid conﬂict with pre-
vious documents, a singular deﬁnition for classifying events
by timing is of value. We propose that the timing categories
expounded in the endovascular abdominal and thoracic
reporting standards document be adopted for all peripheral
vascular interventions. Periprocedural events are those
occurring #30 days after the index procedure. Short-term events are those occurring more than 30 days but
6 months or less after the index procedure. Midterm events
occur between 6 months and 5 years, and long-term events
are those that occur after 5 years. In each case, the timing
of the event should be the precise time point at which the
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example, the loss of primary patency of a femoropopliteal
bypass graft should be recorded on the date an objective
imaging study documents occlusion rather than on the
date of the patient’s development of symptoms because
symptoms may occur from a stenosis before occlusion,
and the loss of primary patency is deﬁned at the time of oc-
clusion irrespective of prior stenosis.a The terms nonhemispheric and vertebrobasilar have been used interchange-
ably in the past. For clarity, it is recommended that the term vertebrobasilar
be used, deﬁning posterior deﬁcits that originate from the vertebral or
basilar arteries (eg, embolization from a subclavian artery lesion or hypoper-
fusion from bilateral vertebral artery disease).REPORTING EVENTS SPECIFIC FOR DEVICE
USE IN THE ARTERIAL SYSTEM
The use of medical devices for peripheral arterial proce-
dures is associated with adverse events that may be quite
different from those that occur in the venous system, the
heart, or the intracranial vasculature. Within the context
of the peripheral arterial procedures, however, particular
adverse events are common to each speciﬁc category of de-
vice used to treat arterial disease. Whereas the frequency of
such events may differ among devices and anatomic re-
gions, the characteristics of the events are often similar
and thus lend themselves to a standardized consideration.
This principle holds true for events within any one organ
system or disease entity, a principle underlying the organi-
zation of this document into system-speciﬁc subsections.
An adverse event potentially common to all open or
endovascular arterial interventions is periprocedural
myocardial infarction (MI). As such, it warrants a standard-
ized deﬁnition for reporting its occurrence. MI is tradition-
ally deﬁned by World Health Organization criteria to
include electrocardiographic and cardiac enzyme end
points.3 The Carotid Revascularization Endarterectomy
versus Stenting Trial (CREST) study deﬁned MI when
either creatine kinase (CK) MB isoenzyme or troponin
levels were at least two or more times the upper limit of
normal occurring with either ischemic symptoms or new
ST-segment depression or elevation of more than 1 mm
in at least two contiguous leads.4 Periprocedural MI, how-
ever, often occurs without symptoms because of anesthesia
or sedation, and electrocardiographic changes can be ab-
sent, transient, or subtle. As well, CK has limited accuracy
because of skeletal muscle injury, even with MB isoen-
zymes, although this is less of an issue for carotid proce-
dures than for major abdominal, thoracic, or lower
extremity vascular operations.5 Last, one must be cogni-
zant of abnormalities in cardiac markers occurring as a
result of concurrent diseases. For instance, troponin levels
may be elevated from renal insufﬁciency.6 A universal deﬁ-
nition of MI was published by the joint European Society
of Cardiology/American College of Cardiology Founda-
tion/American Heart Association/World Heart Federa-
tion Task Force for the Redeﬁnition of Myocardial
Infarction, suggesting the use of troponin T or I rather
than CK or CK-MB in concert with electrocardiographic
changes to deﬁne MI in clinical trials.7 An increased
troponin value is deﬁned when at least one value is above
the 99th percentile for a normal population, speciﬁc for
each individual assay. This universal deﬁnition of MIshould be used for future peripheral vascular medical device
trials.
Carotid artery procedures. The use of medical de-
vices in the carotid artery is associated with periprocedural
adverse events common to other procedures as well as a
unique set of events speciﬁc to the cerebrovasculature.
The frequency of such events has been shown to be associ-
ated with certain baseline patient characteristics, both de-
mographic and anatomic.8 The relationship between
baseline characteristics and outcome fostered the classiﬁ-
cation of patients into normal and high-risk categories for
carotid angioplasty and stenting. This classiﬁcation is
beyond the scope of this document, but it is important to
record and to report demographic characteristics and
relevant anatomic characteristics, including those of the
aortic arch in addition to the carotid vessels.
Neurologic events. Carotid procedures are by and
large prophylactic, undertaken to prevent stroke, and yet
the primary periprocedural complications are neurologic
events. Neurologic events should be classiﬁed by duration,
etiology, location, and severity. Transient ischemic events
are deﬁned as neurologic deﬁcits lasting 24 hours or less;
longer deﬁcits meet deﬁnition of stroke. Amaurosis fugax
and retinal strokes should be reported separately. It is
important to report new infarcts on imaging studies irre-
spective of symptoms, but asymptomatic infarctions should
be reported and tabulated separately. Newer, more sensi-
tive imaging studies allow identiﬁcation of smaller, often
asymptomatic defects. In an effort to allow comparison of
future studies to prior reports, the clinical criteria for tran-
sient ischemic events and stroke should not be abandoned.
Rather, it is recommended that future studies classify
events as “clinical events,” “anatomic events,” or events
with both clinical and anatomic ﬁndings.
Hemorrhagic events should be differentiated from
ischemic events, and hemorrhagic transformation and
parenchymal hemorrhage should be subclassiﬁed under
ischemic events when bleeding is a secondary process after
ischemic infarction. The location of a stroke should be re-
ported as ipsilateral, contralateral, bilateral, or vertebrobasi-
lar.a Global symptoms from noncerebrovascular causes or
from the hyperperfusion syndrome should be differentiated
from diffuse bilateral ischemia caused by ischemic infarc-
tion. The severity of the event should be reported with
the National Institutes of Health Stroke Scale (NIHSS)
to rate clinical severity of a stroke and the modiﬁed Rankin
scale to assess functional outcome after stroke. The NIHSS
and Rankin scale should be performed before a procedure
as a baseline and after the intervention.9
Neurologic events, whether transient or permanent,
can be either procedure or device related. To classify the
causality or relatedness of the event, one must ask the
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the device had performed at 100% of expectations. If the
answer is yes, the event should not be considered device
related. For example, consider two patients with stroke
occurring within the ﬁrst 24 hours after carotid stenting,
one purely hemorrhagic and the other ischemic. The hem-
orrhagic stroke is unlikely to be related to the stent. Most
early hemorrhagic strokes occur as a result of disturbed
intracranial arterial autoregulation, periprocedural hyper-
tension, antiplatelet/anticoagulant therapy, and other less
well described mechanisms that are by and large unrelated
to the stent.10 For this reason, such an event would be clas-
siﬁed as procedure related and not device related. By
contrast, an ischemic stroke usually occurs from stent-
related complications, such as postdeployment emboliza-
tion or stent occlusion, each of which would be device
related. The ischemic stroke would be considered to be pro-
cedure related only if one were certain that it occurred from
emboli dislodged from an atherosclerotic arterial surface
with guide or wire manipulation. Otherwise, such proce-
dural neurologic events should be classiﬁed as device related.
Whereas some may disagree with the pathophysiology of
these examples, each is included to illustrate the principle
that complications that occur irrespective of the perfor-
mance of the study device should be considered procedure
related, and those due to anything less than optimal device
performance should be considered to be device related.b
Non-neurologic events. Common non-neurologic
events that occur after percutaneous carotid interventions
include periprocedural MI, bradycardia, hypertension and
hypotension, and access site complications. With the
exception of access site complications, the same adverse
events occur after carotid endarterectomy. Cervical wound
hematoma, wound infection, and cranial nerve injuries may
also occur after endarterectomy. Most non-neurologic
adverse events are classiﬁed as procedure-related and not
device-related events.
Composite end points. The occurrence of adverse
events has been employed as an end point in clinical trials
to characterize the safety of medical devices. Primary end
points should measure outcome that is not only clinically
relevant to a patient but also of similar connotation from
patient to patient. Composite primary end points can be
problematic in this regard. An apparent equivalence of
the primary composite end point may obscure the impor-
tance of any individual component to a patient in the
decision-making process. Whereas the expediency of a
composite end point for sample size considerations cannot
be ignored and will continue, individual end point com-
ponents of the composite should be separately reported
and tested statistically.
As an illustration, the primary end point for many ca-
rotid trials has been the composite of stroke, death, orb Performance includes introduction and deployment of the device under
study but does not include the performance of adjuvant devices, such as
guidewires and guides, that are not supplied with the device as components
of a kit.MI. Carotid interventions are performed to prevent stroke,
and yet efﬁcacy has been quantiﬁed by an end point that
assigns an equal importance to MI. For example, two pro-
cedures, one with stroke and myocardial rates of 5% and 1%
and the other with rates of 2% and 4%, would be judged
similarly, obscuring the option for a patient to place greater
importance on the rate of stroke than on the rate of MI.
Aortic aneurysm repair. The repair of an aortic aneu-
rysm can be accomplished safely with either open surgical
or endovascular procedures in most patients with suitable
anatomy. Endovascular aneurysm repair (EVAR) was
developed with the hope of diminishing the risk of periop-
erative complications associated with open surgical repair,
particularly in elderly or frail individuals.11 EVAR has
now surpassed open surgical repair in the frequency with
which it is performed, both for elective aneurysms and in
some centers for ruptured aneurysms as well.12,13 EVAR is
associated with a marked reduction in procedure-related
adverse events but at the cost of an increased rate of
device-related complications during long-term follow-up.14
A wide range of distant complications can occur after
either endovascular or open surgical repair of aneurysms,
although at different frequencies. Most of these are not
device-related events (eg, perioperative MI, pneumonia,
and urinary retention). Such events are classiﬁed as proce-
dure related only to the extent that they occur within
30 days of the index procedure or a reintervention. Other
events, such as distal embolization, renal artery occlusion,
and graft limb occlusion, can occur after open or endovas-
cular repair but have been somewhat more commonly
observed with the latter.
Complications associated with the use of a standard
surgical graft include graft occlusion, anastomotic stenosis,
graft kinking, anastomotic false aneurysm formation, graft
infection, and late graft dilation from fabric degeneration.
To a certain extent, these also occur after EVAR. The gen-
eral guidelines for determining the relatedness of these
events should be followed, asking whether the complica-
tion might still have occurred even if the graft had per-
formed entirely as expected. As examples, graft occlusion
and late fabric degeneration would be device-related
events, whereas graft infection would usually be procedure
related.c There are no absolute rules in this regard, and
each event should be classiﬁed after review of the unique
circumstances surrounding its occurrence.
Surgeons are increasingly employing hybrid procedures
to reduce the morbidity of a completely open surgical solu-
tion to complex or proximal aneurysms. Hybrid procedures
include extra-anatomic bypasses such as carotid-subclavian,
visceral and renal artery bypasses, carotid-carotid bypass,
and bypasses from the ascending aorta. Each is used to
extend the length of the available landing zone in conjunc-
tion with endograft implantation. When a complication is
directly related to the open surgical portion of a hybridc An exception would be an antibiotic-impregnated graft, the primary per-
formance objective of which is to prevent infection. In these devices, graft
infection might be considered to be a device-related complication.
Table II. Relatedness and imaging characteristics of
endoleaks
Endoleak Relatednessa
Imaging characteristics for reporting
purposes
Ia Device Contrast material in the aneurysm
sac adjacent to the proximal seal
zone and/or between the
endograft and the inner wall of
the proximal attachment site
Ib Device Contrast material in the aneurysm
sac adjacent to the distal seal zone
and/or between the endograft
and the inner wall of the distal
attachment site
II, lumbar Procedure Contrast material along the
posterior sac wall with
visualization of lumbar or
intercostal arteries
II, IMA Procedure Contrast material along the left
anterior sac wall with
visualization of the IMA
III Device Contrast material in contact with
the endograft, not in direct
contact with the neck
IV Device Contrast material in contact with
the endograft, usually diffuse,
resolved on follow-up
V Device Sac enlargement without contrast
material in sac, even on delayed
views
IMA, Inferior mesenteric artery.
aLate type I endoleaks can occur from dilation at an attachment site, and
migration or modular disconnection can occur from conformational
changes after sac contraction.63 Such events may be classiﬁed as unrelated to
the device. A Clinical Events Committee or other impartial observer may be
of assistance in such determinations.
d The classiﬁcation of endoleaks can at times be an art rather than a science.
Even core laboratory evaluation of endoleaks is fraught with inaccuracies
because of the impossibilities of adequate visualization of ingress and egress
sites in many instances.
e Devices that ﬁll the aneurysm sac with polymer or other materials are ex-
ceptions to this rule; in these cases, type II endoleaks from the lumbar ar-
teries or the inferior mesenteric artery would be considered to be device
related.
f An exception to this caveat is devices for which one of the primary perfor-
mance goals is to prevent type II endoleaks. In such a device, a type II endo-
leak would be considered to be device related.
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gard to the endograft but device related with respect to the
standard surgical graft. Occlusion of an extra-anatomic graft
during an aortic debranching procedure is an example of
such a complication.Newer techniques employed in a formal
clinical trial (eg, on-table fenestration, chimney, petticoat,
and sandwich techniques) are associated with a number of
device- and procedure-related adverse events that increase
proportionately with increasing device complexity.
Events speciﬁc to EVAR. The advent of endovascular
repair created a set of novel complications not observed with
traditional aneurysm repair. Foremost in this regard are
endoleaks, but access vessel complications, endograft migra-
tion, device component failure, contrast-induced nephrop-
athy, and radiation exposure occur signiﬁcantly more often
with endovascular than with open surgical repair.
The presence or absence of an endoleak is not difﬁcult to
ascertain on computed tomography (CT) imaging studies,
and the use of delayed views will increase the sensitivity of
detection. By contrast, classiﬁcation of the type of endoleak
can be problematic. The use of combined imaging modal-
ities, for instance, CT and angiography, duplex ultrasound,
or dynamic CT, may increase the accuracy of endoleak clas-
siﬁcation, but clear delineation is often impossible. As well,the visualization of lumbar or inferior mesenteric artery
does not by any means conﬁrm a type II leak; high-
pressure endoleaks are often accompanied by ﬂow of
contrast material into these branch vessels as sites of egress.
Standard guidelines for classiﬁcation of endoleaks can
improve standardization, and these are offered herein
(Table II). It should be understood that these are included
as general guidelines only. Accurate endoleak classiﬁcation
can be achieved only through the use of often time-
consuming complex angiographic and other imaging
studies that, if patient management will not be altered,
may not be performed. As well, the review of serial imaging
studies in concert rather than a single study at a snapshot in
time may increase the accuracy of endoleak classiﬁcation.
For example, a diffuse contrast blush around an endograft
at completion angiography may be a type III or, more
likely, a type IV endoleak. The disappearance of the blush
on the ﬁrst follow-up CT would lend one to believe that
the endoleak was type IV.d In this regard, it is useful to
report whether an endoleak appears intraprocedurally or
during short-term, midterm, or long-term follow-up
because the underlying etiologic mechanisms can differ
considerably on the basis of when the endoleak occurs.
Type I endoleaks occur from either failure of adequate
circumferential apposition of the endograft to the aortic
wall (sealing) or malposition of the device at an unintended
location. Improper position of the endograft can occur un-
intentionally at the time of initial deployment (misdeploy-
ment) or thereafter (migration). In either case, the
complication is classiﬁed as a device-related adverse event,
illustrating the concept that adverse events that occur
from operator error are still classiﬁed as device related.
Type I leaks should be characterized by whether they occur
at the proximal (type Ia) or distal (type Ib) attachment sites.
As mentioned in Part One of this document, most type
II endoleaks should be considered to be procedure-related
and not device-related adverse events.e They meet the ISO-
14155 deﬁnition of an adverse event as an abnormal labo-
ratory ﬁnding that at least in some cases can result in the
untoward occurrence of aneurysm sac enlargement.15 As
well, the presence of a type II leak often alters imaging
follow-up protocols with additional radiation exposure
from additional CT imaging. Because the current belief is
that type II endoleaks occur independently of the perfor-
mance of currently marketed endografts, they would be
procedure- and not device-related adverse events.f Most
Table III. Suggested composite safety end points for
open surgical and endovascular repair of abdominal and
thoracic aneurysms
Abdominal aortic
aneurysm repair
Thoracic aortic
aneurysm
repair
Open EVAR FEVAR Open TEVAR
Aneurysm-related death X X X X X
MI X X X X X
Graft limb occlusion X X X
Respiratory insufﬁciency X X X X X
Renal insufﬁciency X X X X X
Paraplegiaa X X X
Intestinal ischemia X X X X X
Arm ischemia X X
Stroke X X
EVAR, Endovascular aneurysm repair; FEVAR, fenestrated endovascular
aneurysm repair; MI, myocardial infarction; TEVAR, thoracic endovascular
aneurysm repair.
aParaplegia occurs rarely with infrarenal procedures but is a devastating
complication when it does occur. Inclusion as a component of a composite
end point may be appropriate.
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leak is not masquerading as a type II endoleak in disguise.
Other adverse events that occur after EVAR include
modular disunion (component separation, a type III endo-
leak), limb kinking or occlusion, thromboembolism, and
access vessel complications. Complete device thrombosis
can occur on rare occasions. Renal insufﬁciency is now
recognized as a complication of EVAR and can be device
related from compromise of the renal ostia from suprarenal
stent struts (with or without local dissection), cranial mis-
deployment, or proximal (“reverse”) migration of the de-
vice. Concomitant deployment of a renal or visceral stent
that produces renal functional or anatomic injury must be
considered procedure related unless the stent is an intrinsic
component of the speciﬁed device under study. Renal
insufﬁciency can also be a procedure-related adverse event
from contrast-induced nephropathy after angiography or
repeated CT imaging. Renal insufﬁciency can also occur
from embolization at the time of implantation, an event
that can be procedure related if it occurred independently
of the endograft or device related if it was demonstrated
to have occurred during device introduction and
deployment.
Fenestrated devices are now approved by the Food
and Drug Administration for marketing in the United
States. Fenestrated endovascular aneurysm repair (FEVAR)
is often performed with a variety of devices.16 For instance,
the fenestrated device is usually used in conjunction
with renal or visceral stents or stent grafts that may or
may not be components of the fenestrated device itself.
Branched endografts for repair of suprarenal and thora-
coabdominal aortic aneurysms are similar in this re-
gard.17,18 It can be difﬁcult to ascribe causality to one
device or another when complications arise. For this reason,
events directly related to an adjunct device (eg, thrombosis
of a covered renal stent) should be classiﬁed as device
related in FEVAR and branched endograft procedures.
Thoracic endovascular aneurysm repair (TEVAR), like
EVAR, carries the risk of endoleak and migration, but the
risk of paraplegia becomes more signiﬁcant. Paraplegia can
occur irrespective of the device performance and should be
classiﬁed as a procedure-related event. The logic of related-
ness here is similar to that for type II endoleaks but in
reverse. Type II endoleaks occur from persistence of retro-
grade branch ﬂow, whereas paraplegia occurs from inade-
quate branch ﬂow, in both cases irrespective of the
intended device performance. Arm ischemia is similar;
when it is due to coverage of aortic branch vessels, the
complication is a procedure-related event.
Composite safety end points. The occurrence of ma-
jor adverse events (MAE) has been employed as a compos-
ite end point to characterize the safety of endovascular
repair in comparison to open surgical repair. MAE include
the occurrence of death, MI, stroke, renal failure, respira-
tory failure, paraplegia, and bowel ischemia. Endograft
marketing approval has been, in part, based on the rate
of MAE in comparison to a historical open surgical cohort,
the SVS Lifeline Registry. Whereas the use of MAE as aprimary measure suffers from all the limitations of any com-
posite end point, MAE were well-deﬁned in the Lifeline
control series of patients undergoing open surgical aneu-
rysm repair, a control cohort that, for reasons of patient
selection for open repair, may no longer be possible to
reproduce. In this regard, the same deﬁnitions must be
used in subsequent EVAR trials that seek to use the Lifeline
open surgical group as a historical control.
If not constrained to the Lifeline data as a historical
control group, the use of an alternative composite safety
end point that includes aneurysm-related mortality instead
of all-cause mortality can be considered to decrease the sta-
tistical noise of the analysis. Aneurysm-related mortality is
deﬁned as any death that occurs within 30 days after
endograft implantation or within 30 days after a secondary
procedure performed for an indication related to the aneu-
rysm or any death resulting from aneurysm rupture. Graft
limb occlusion should also be considered in the composite
end point for infrarenal endografts, eliminating stroke and
possibly paraplegia. By contrast, a relevant composite safety
end point for thoracic endograft studies might include
stroke, paraplegia, symptomatic arm ischemia, and respira-
tory failure in addition to aneurysm-related mortality
(Table III).
Peripheral arterial revascularization procedures.
Reporting standards for peripheral arterial revascularization
are most commonly performed in the lower extremity, and
as such, this section has focused on endovascular and open
surgical procedures in the leg. Space does not allow a
consideration of the myriad other revascularization proce-
dures on the renal, mesenteric, upper extremity, or other
anatomic segments. Nonetheless, most of the principles
for lower extremity adverse event reporting may be trans-
lated to the less frequently performed procedures in these
other arterial systems.
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two important criteria that must be speciﬁed in reporting
adverse events after lower extremity revascularization.
The treated arterial segment or “target lesion” is of great
relevance so that one may discern failure of an intervention
from progression of disease elsewhere. For example, in a
patient who underwent stent placement at the mide
superﬁcial femoral artery level, it would be important to
separate the adverse event of recurrent claudication caused
by an in-stent restenosis from the same symptoms occur-
ring as a result of progression of disease at the superﬁcial
femoral artery origin. Often even more precise anatomic
speciﬁcation is necessary, such as in grading the degree of
restenosis. For instance, if a stent were incompletely
expanded at a focal point along its length, a recurrent
stenosis in this area should be quantiﬁed by luminal
reduction at this location rather than in relation to a more
completely treated spot. This differentiation attains
importance in the separation of “residual” from “recur-
rent” stenoses. The residual stenosis may be a mechanical
problem during post-stent angioplasty, whereas the recur-
rent stenosis may relate to the complexities of in-stent
intimal hyperplasia.
The second important criterion to specify is the timing
of an event in relation to the index procedure. The classiﬁ-
cation into acute (30 days or less), subacute (between
30 days and 12 months), and late (beyond 12 months)
has become standard in the peripheral endovascular litera-
ture. There is some logic behind the timing of these cate-
gories. They roughly correspond to the long-standing
concepts of the underlying process of bypass graft failure:
early due to technical issues or poor patient selection,
midterm due to intimal hyperplasia, and late due to pro-
gression of disease.
Combination devices. Some devices are composed of
combinations of components, wherein it is useful to classify
events related to an individual component rather than to
the device as a whole. For example, adverse events directly
associated with the use of a drug-eluting stent, although all
device related, may be related to the metallic stent or to the
drug. Late stent thrombosis and acute neutropenia from
eluted antiproliferative drug would both be device-related
adverse events. It is useful, however, to subcategorize
these as stent related and drug related, respectively,
whenever possible.
Baseline characteristics. The characteristics of a lower
extremity lesion before the index procedure should be
recorded in any study of a peripheral arterial intervention.
The Fontaine criteria were developed in the 1950s as a
means to classify the severity of lower extremity ischemia
in patients considered for surgical revascularization.19
Baseline clinical status has most frequently been reported
with the guidelines enumerated by Rutherford and col-
leagues in the revised lower extremity reporting standards
document published in 1997.20 The three “Rutherford
categories” of acute limb ischemia and the six categories of
chronic ischemia remain a useful framework. Anatomic
criteria are of utmost importance, as are the noninvasivelaboratory ﬁndings (Doppler ankle index or toe-brachial
index if the ankle pressures are unobtainable). An SVS
lower extremity threatened limb classiﬁcation framework
based on the wound, the severity of ischemia, and the foot
(WIfI) was developed more recently.21 The WIfI system
addresses some of the limitations of prior systems, partic-
ularly with respect to arterial perfusion as the sole param-
eter in prior schemes. The WIfI system addresses the
wound and infection as two additional determinants of
outcome and may provide a more meaningful and objective
assessment of the baseline status of a patient.
For open revascularization, the inﬂow and outﬂow ves-
sels should be speciﬁed, and the number of patent tibial ar-
teries should be recorded for endovascular or open
revascularizations of the superﬁcial femoral or popliteal ar-
teries. The target lesion diameter and length should be
speciﬁed, but the accurate determination of each can be
problematic. It is possible to calculate the severity of a ste-
nosis by percentage diameter reduction only if the normal
diameter of the vessel is known, a variable that can be
impossible to estimate in the setting of diffuse peripheral
atherosclerosis. Lesion length can be even more difﬁcult
to determine, noting the nonfocal nature of peripheral
atherosclerosis. As an approximation to yield a modicum
of standardization, the lesion length can be speciﬁed as
that length over which the disease is severe enough to war-
rant intervention, but this will always be subjective and
open to interpretation.
Target lesions and target vessels. It is useful and
customary to specify events that are related to the target
lesion, the target vessel, and the target extremity.
Currently, target lesions should be classiﬁed by the grading
scheme in the TransAtlantic Inter-Society Consensus
(TASC II) document on the management of peripheral
arterial disease, A through D.22 Complications related to
the target lesion are those that relate to the treated segment
including 5 mm proximal and 5 mm distal to the treated
lesion.23 The target vessel can involve two anatomic arterial
segments if they are in continuity without large branches
(eg, the external iliac and the common femoral arteries, or
the superﬁcial femoral and the popliteal arteries). As an
example, after placement of a 40-mm stent at the proximal
adductor canal, the target lesion is the superﬁcial femoral
artery including 5 mm proximal and distal to the stented
segment (50 mm in length), and the target vessel would
include the superﬁcial femoral and popliteal arteries. It is
evident that certain events are best described with reference
to the target lesion (eg, restenosis), whereas others are
applicable to the target vessel (eg, thrombosis) or to the
target extremity (eg, amputation from infection). As well,
the precise location of a target lesion may be difﬁcult to
identify after interventions that do not leave an implant
behind (eg, after balloon angioplasty). In such cases, end
points related to reinterventions within the target vessel
may be more reliable than those that are speciﬁc to the
target lesion.
Loss of patency. Among adverse events that occur af-
ter lower extremity revascularization, loss of patency is
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as is sometimes observed with a tongue of mural thrombus
originating from the thrombogenic surface of a vessel after
angioplasty or stenting. Alternatively, the lumen obstruc-
tion may be complete, with loss of patency. Patency has
been deﬁned by three different measures: primary,
primary-assisted, and secondary patency. The most sensi-
tive is primary patency, deﬁned as freedom from occlusion
or reintervention.g Reinterventions to treat lesions at a
graft anastomosis also trigger a loss of primary patency.h
Primary-assisted patency is deﬁned as freedom from oc-
clusion irrespective of whether an intervention was per-
formed; in other words, primary-assisted patency is not lost
when a reintervention is performed to preserve patency
before occlusion occurs. Last, secondary patency is deﬁned
as freedom from “permanent” loss of patency determined
through the last follow-up time point for each patient.i As
long as the graft or vessel is patent at the point of last follow-
up, secondary patency has been preserved irrespective of the
number of reinterventions. If, however, the graft or vessel is
occluded at the last follow-up, the time point for loss of
secondary patency is the point at which the last occlusive
event was documented with imaging studies or operation. In
this context, however, it is recommended that replacement
of more than 50% of the length of a graft or revision of the
graft to a more distal outﬂow vessel trigger loss of secondary
patency. It is also recommended that excision of a patent
graft (eg, as occurs with graft infection) should not be
considered to be a loss of patency. Although it is important
as an end point in and of itself, graft excision should be
tabulated separately, for example, as an infectious rather than
an occlusive complication. Such a patient would be excluded
from further patency analyses as a censored data point in a
Kaplan-Meier or similar analysis.
A similar classiﬁcation system for patency can be used
for angioplasty with or without stenting in the peripheral
arteries. Primary patency is deﬁned as freedom from occlu-
sion or reintervention in a segment of artery treated with
angioplasty or stent placement. Primary-assisted patencyg Occlusion of an open surgical or endovascular intervention that occurs
before leaving the operating room or angiography suite is still considered
to be a loss of primary and primary-assisted patency. By contrast, additional
interventions performed at the time of the index procedure and in the
absence of occlusion do not constitute a loss of primary patency.
h A clinician may or may not elect to intervene on a stenosis, and depending
on the rigor of postoperative surveillance, some stenoses may go undetected
and untreated. Thus, although sensitive, primary patency loses some objec-
tivity as a measure of graft function. A composite end point of freedom from
occlusion or signiﬁcant stenosis adds back some impartiality but begs the
question of how to deﬁne a signiﬁcant stenosis. In studies with duplex ultra-
sound follow-up, a 50% reduction in diameter can be used to deﬁne a sig-
niﬁcant stenosis. Similarly, when follow-up is limited to angiography, a
late lumen loss to 50% of its immediate postintervention value can be used.
i It is evident that secondary patency may depend on the duration of follow-
up to the extent that the occlusion and the restoration of patency are sepa-
rated in time. As an example, if a graft occludes at 11.5 months and a
thrombectomy is performed at 12.5 months, the graft would be considered
to have lost secondary patency with a total trial observation period of
12 months but would be considered to have maintained secondary patency
if the observation was made at 13 months.is deﬁned as freedom from occlusion in the treated arterial
segment, allowing reintervention to preserve patency.
Thus, primary-assisted patency is not lost after a reinterven-
tion as long as occlusion did not occur. As is the case with
grafts, secondary patency is deﬁned as successful recanaliza-
tion of an occluded segment of artery that had previously
been treated by angioplasty or stenting. Secondary patency
can also be expressed with Kaplan-Meier techniques, but
the deﬁnition of loss of secondary patency must be consid-
ered retrospectively at the point of the last follow-up for
each patient.
Thrombosis vs occlusion. Vascular surgeons have
traditionally used the terms thrombosis and occlusion inter-
changeably to indicate lost patency of a bypass graft or endo-
vascular intervention.20,24 By contrast, the term stent
thrombosis has had a different connotation after coronary artery
interventions.25 Noting an offset in the anti-restenotic beneﬁt
of drug-eluting stents because of an increased rate of acute
coronary events, the term stent thrombosis has been reserved for
mural intrastent thrombus formation, a ﬁnding that often
followed discontinuation of dual antiplatelet therapy. The
Academic Research Consortium deﬁned deﬁnite coronary
stent thrombosis when occlusive or nonocclusive thrombus
was observed angiographically, concurrently with ischemic
symptoms or elevation of cardiac biomarkers, or when intra-
stent thrombus was retrieved at thrombectomy or autopsy.26
This deﬁnition of thrombosis, appropriate to the coro-
nary setting, can result in reporting inconsistencies and
misinterpretation of results when it is used in the periph-
ery.27 We recommend continued interchangeable use of
the terms thrombosis and occlusion to refer to the complete
loss of patency after open or endovascular peripheral inter-
ventions. That said, it may be useful to tabulate the periph-
eral vascular corollary of coronary stent thrombosis when
drug-eluting stents or balloons are used. As an alternative
term, drug-related thrombus formation can be employed af-
ter drug-eluting interventions when imaging ﬁndings or
direct visual inspection conﬁrms mural thrombus without
an underlying restenotic or residual lesion.
Late lumen loss. The concept of late lumen loss orig-
inated in the coronary literature and is unfamiliar to many
peripheral vascular surgeons, who commonly use percent-
age diameter reduction to gauge stenosis. Late lumen
loss, however, warrants consideration as an accurate and
reproducible end point.28 Late lumen loss may have
some advantages over percentage diameter reduction in
angiographic follow-up because the normal diameter of the
vessel may be difﬁcult to determine from luminal contrast
studies alone.j In such cases, the minimum luminal diam-
eter is measured across a lesion and can be expressed as a
single measurement in millimeters or as the change fromj Percentage diameter reduction is still applicable to the determination of ca-
rotid bifurcation stenoses, in which the infrequency of disease beyond the
ﬁrst few centimeters of internal carotid artery allows estimation of the
normal vessel diameter, as is used in the NASCET criteria. By contrast,
no such approximation of normal vessel caliber is often possible in lower ex-
tremity stenoses, and in such cases the ability to reliably determine the de-
nominator for the calculation of percentage stenosis is not possible.
Table IV. Procedure and device relatedness after device
use in the venous system
Device
Relatedness
Procedure Device
Venous access devices
Catheter occlusion X
Infection X
Venous thrombosis, stenosis,
pulmonary embolism
X
Extravasation of infusate X X
Catheter fracture during implantation X
Catheter fracture during long-term
follow-up
X
Arterial injury and arteriovenous ﬁstula X
Superﬁcial venous ablation devices
Wound infection X
Skin necrosis, neurapraxiaa X X
Superﬁcial thrombophlebitis X
Deep venous thrombosis X
Vena caval ﬁlters
Deep venous thrombosis X
Inferior vena caval occlusion X
Filter migration or embolization X
Pulmonary embolism X
Filter tilt X
Venous angioplasty and stenting
Occlusion of target lesion or target
vessel
X
Restenosis of target lesion X
Stent fracture X
Stent migration X
Deep venous thrombosis Xb
Pulmonary embolism X
The assignment of relatedness is included as a guide; differences will arise on
the basis of individual clinical scenarios.
aInjury to surrounding tissues can be a result of inadequate tumescent
inﬁltration of local anesthetic, in which case the complication is procedure
related. Otherwise, the event would be device related.
bDeep venous thrombosis is commonly unrelated to the device or to the
procedure; rather, it is a consequence of a patient’s hypercoagulability. If,
however, it develops within the target lesion, it would be device related.
JOURNAL OF VASCULAR SURGERY
220 Ouriel et al July 2014the minimum luminal diameter achieved immediately after
the index procedure.k The terms residual stenosis and
restenosis are important to differentiate; residual stenosis
implies failure of the index procedure, whereas restenosis
signiﬁes the development of a new stenosis within the
target lesion. Residual stenosis has been deﬁned when a
$30% in diameter stenosis reduction remains after inter-
vention.29 Binary restenosis is deﬁned when a $50% in
diameter lesion recurs as documented angiographically,
with duplex ultrasound (eg, peak systolic velocity ratio
>2.4), or by direct visual inspection.30
Reinterventions. The concept of target lesion revas-
cularization (TLR) was introduced for coronary interven-
tions in the mid-1990s.9 Target vessel revascularization
and, to a lesser extent, target limb revascularization are also
end points that have become popular and differ from TLR
only in the speciﬁcity of the vascular segment under
consideration. The TLR and target vessel revascularization
are procedures and not adverse events. The adverse event is
the associated condition responsible for the reintervention
(eg, stent thrombosis).
Whereas TLR is commonly employed as an end point
in coronary and peripheral interventional studies, a degree
of subjectivity is impossible to eliminate. The clinician is
responsible for determining whether to re-treat a lesion
and thereby trigger the end point, an issue of particular
concern in unblinded studies. Nevertheless, TLR is a useful
end point when serial imaging studies are impractical, such
as in the coronary circulation. The use of an imaging
cohort may be advantageous in such cases. Each subject
in the imaging cohort undergoes a speciﬁed study
(eg, angiography or duplex ultrasound) at predeﬁned
time points, providing an additional level of objectivity.10
Another method of adding objectivity to an analysis is to
specify whether a reintervention is “clinically driven,” a
term used to discern those reinterventions that are related
to an objectively documented lesion (eg, signiﬁcant reste-
nosis or occlusion by angiography, duplex ultrasound, or
changes in ankle-brachial index) or to the development
of speciﬁc clinical symptoms appropriate to a failing or
failed intervention.
End points to assess device safety. The composite
end point major adverse limb events (MALE) is a useful
measure of safety after lower extremity endovascular or
open surgical procedures. MALE was introduced in an
article by Conte on behalf of the Society for Vascular Sur-
gery in 2009 and was deﬁned as an above-ankle amputa-
tion or major reintervention including placement of a new
bypass graft, interposition graft, thrombectomy, or
thrombolysis.31,32 Balloon angioplasty, stenting, atherec-
tomy, and minor open surgical revisions such as patch
angioplasty were not considered to be majork It is suggested that measurements be made along the length of the target
lesion as the smallest luminal diameter. For instance, if the smallest diameter
is 6 mm on the postintervention angiographic study and 3 mm on a follow-
up angiogram, the restenosis would be considered signiﬁcant even if the two
measurements were made at different points along the length of the target
lesion.reinterventions. If a composite end point is desired, the
primary safety end point for lower extremity arterial studies
should be a composite of MALE and periprocedural death.
Key safety secondary end points include MALE alone and
major adverse cardiovascular events, which include MI,
stroke, and all-cause mortality. As with any composite end
point, one must separately consider each individual
component because the combination of disparate out-
comes may confound relevant differences in any single end
point. For endovascular interventions, other important
safety end points include access site complications (hema-
toma, false aneurysm, arteriovenous ﬁstula, infection). For
open surgical procedures, bleeding, infection, and wound
complications should be reported.
Thrombolytic therapy and percutaneous mechani-
cal thrombectomy. Intra-arterial, catheter-directed
thrombolytic therapy and percutaneous mechanical
thrombectomy (PMT) are associated with their own set of
efﬁcacy end points and complications. Whereas
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in this document because of the frequency with which
thrombolysis is accompanied by the use of specialized
catheters, balloons, and ultrasound systems. The outcome
of thrombolytic therapy and PMT should be considered in
the context of the anatomic goals appropriate to the
unique clinical presentation. The “target segment” per-
tains to the anatomic segment that is the objective of the
intervention and should be speciﬁed by the clinician at the
outset of therapy. The target segment usually ﬁts the
criteria for a target vessel (often a bypass graft) rather than
for a target lesion, noting the frequent propagation of
thrombus to the next largest proximal and distal branches
within a vessel.l
Seldom is sole thrombolytic therapy or PMT enough to
provide a long-lasting solution;more often, successful recan-
alizationmust be followed by an endovascular or open surgi-
cal intervention to correct the underlying unmasked lesion
responsible for the occlusion.33 For this reason, adverse
events after thrombolytic therapy and PMT should include
the complications that arise from subsequent intervention
for remediation of an underlying lesion. That said, it is still
useful to subcategorize adverse events into those that are
directly related to the drug (eg, distant hemorrhage), those
that are related to the access site (eg, hematoma and false
aneurysm formation), and those that are related to the pro-
cedure itself (distal embolization, arterial dissection). Hem-
orrhagic complications should be classiﬁed by a standardized
scheme.Whereas theThrombolysis inMyocardial Infarction
(TIMI) classiﬁcation was originally developed in the 1980s
for intravenous coronary thrombolysis, it has been widely
used as a measure for reporting hemorrhagic complications
after peripheral interventions.34 Newer criteria, such as the
Bleeding Academic Research Consortium (BARC) classiﬁ-
cation, however, may offer some advantages over older
classiﬁcations.35
REPORTING EVENTS SPECIFIC FOR DEVICE
USE IN THE VENOUS SYSTEM
Venous interventions are growing in both the fre-
quency with which they are being performed and the spec-
trum of technologies available. These technologies are
associated with a growing list of adverse events that in
some cases overlap events occurring in arteries but encom-
pass other issues unique to the venous system. The devices
that are currently used to address venous disease include
those related to venous access, ﬁlters to prevent pulmonary
embolism, devices for ablating superﬁcial venous varicos-
ities, devices to remove venous thrombus with mechanical
or pharmacologic means, and endovascular balloons and
stents to treat venous stenoses. Adverse events related to
dialysis access grafts were the topic of a previous SVSl The a priori speciﬁcation of the target segment is important in gauging ef-
ﬁcacy. As one example, a bypass graft alone may be the target in the example
of an occluded femoropopliteal graft with propagation of thrombus into one
of three patent tibial arteries. The clinician may choose to leave the tibial
thrombus untreated.reporting standards document and are not considered
herein.36 Similar to events occurring in the arterial system,
it is useful to categorize events related to the use of medical
devices in the venous system by their relationship to the de-
vice, to the procedure, or to neither (Table IV). Adverse
events related to the use of venous access for cardiac
rhythm management are not considered, although many
of the complications associated with their use are similar
to those associated with venous access catheters.
Venous access. Central venous access catheters can be
categorized by whether they are tunneled or nontunneled,
whether they access a peripheral vein or central venous
segment, or whether the device employs a percutaneously
accessed reservoir. Adverse events related to the initial de-
vice insertion include failure to access the vessel, access site
hematoma, bleeding from perforation or laceration of the
vein, embolization of the device or portions thereof, and
misplacement of the device into unintended vessels.37-41
Each of these adverse events is often procedure related
rather than device related because they occur from tech-
nical complications rather than from events related to the
device itself. Fracture of a catheter can occur, either as a
device design issue or, more frequently, from malposition
within the subclavian vein, a procedure-related adverse
event.42 During short- and long-term follow-up, infection
of the catheter or of the access site can develop. Infection is
a procedure-related adverse event, except when it develops
from inadequate sterility of the device as manufactured and
packaged. As well, extravasation of infusate can develop as
an event related to a device design or performance issue or
as a procedure-related event from technical issues experi-
enced at the time of device insertion.
Occlusive complications remain a common problem
with indwelling venous devices, including proximal and
distal venous thrombosis, pulmonary embolism, and cen-
tral venous stenosis. Each of these problems is usually pro-
cedure and not device related. Whereas these events may
be related to the bore of a device, for the most part each
occurs from the natural prothrombotic tendency of intra-
vascular prosthetic materials. Peripherally inserted central
catheters are associated with a higher risk of deep venous
thrombosis (DVT) than are larger bore central venous
catheters, particularly in patients who are critically ill or
in those with cancer.43 Pulmonary embolism, by contrast,
is exceedingly rare in association with peripherally inserted
central catheters. In contrast, occlusion of a catheter
lumen, similar to the loss of bypass graft patency, is consid-
ered to be a device-related adverse event.
Clinical studies of venous access devices should include
a safety analysis that tabulates device- and procedure-
related adverse events. Events that occur at the time of
the initial procedure, primarily technical complications,
should be categorized separately from late complications,
such as infection. The length of follow-up for primary
end points should parallel expectations for the duration
of implantation: relatively brief for many central venous
catheters but longer for implanted reservoirs, particularly
where infection can be an issue. The rate of catheter
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efﬁcacy and, as such, can be expressed in terms of primary
and secondary patency rates with deﬁnitions similar to
those after arterial procedures.
Venous ablation procedures. Venous ablation proce-
dures are most often performed to address varicosities of the
lower extremity superﬁcial venous system or arteriovenous
malformations.44-46 Chemical ablations can be compli-
cated by extravasation with tissue necrosis or allergic
response to the therapeutic agent. Extension of thrombus
into the deep system, however, is at least a procedure-related
adverse event but would be considered device related if the
device was responsible for injury to deep venous structures.
Embolization of foam and other materials used for sclero-
therapy would be considered to be a procedure-related
complication. The safety end points for evaluating venous
ablative devices should include untoward events such as
wound infection, skin necrosis, superﬁcial thrombophle-
bitis, DVT, and neurapraxia.47,48 Ablation by energy
transfer with either laser or radiofrequency modalities may
be accompanied by excessive heat transfer, resulting in
cutaneous, subcutaneous, or peripheral nerve injury, each of
which would be considered a device-related event. Alter-
natively, such injuries may be a result of inadequate
tumescent anesthesia, a procedure-related adverse event.49
The event would be classiﬁed as a “device-related, non-
IFU use” adverse event if the injury were due to an inap-
propriately high power selection. It is important to specify
the severity of endovenous heateinduced injury by a stan-
dard classiﬁcation system.50,51 Last, air embolism can occur
after sclerosing procedures, particularly after use of foam
sclerotherapy.52 Like all adverse events, failure of a proce-
dure or device to achieve its therapeutic goals, in this case
complete obliteration, is reported as a clinical failure of
therapy rather than as an adverse event.
Vena caval ﬁlters. Vena caval ﬁlters can be classiﬁed as
temporary or permanent, and many newer devices are
designed to be either. Complications at the access site,
including bleeding and thrombosis, are by and large
procedure-related adverse events. Thrombotic occlusion
of the vena cava, whether or not from the capture of a large
embolus, should be considered a device-related adverse
event,m as should a failed procedure to retrieve a temporary
ﬁlter. Pulmonary embolism after inferior vena cava ﬁlter
placement is a device-related event unless it can be proved
that the embolus reached the lungs through routes other
than the inferior vena cava. With the exception of insertion
site thrombosis, postimplantation DVT is not uniformly
considered a device-related adverse event despite evidence
that its risk is increased after placement of a ﬁlter. One
might, however, consider a DVT after ﬁlter placement a
procedure-related event. By contrast, failure of a device tom Many devices are designed to prevent caval occlusion despite capture of
large emboli. As well, in situ caval thrombosis may occur as a result of the
ﬁlter itself; thus, such events should be considered device related.
n Many devices penetrate through the caval wall by design; clinically signif-
icant perforation includes only those occurrences with hemorrhage, intesti-
nal perforation, aortic penetration, or other relevant consequences.deploy as intended, material fracture, clinically signiﬁcant
caval perforation,n deployment at an unplanned location,
and device migration or central embolization of a ﬁltero are
aberrances of clinical relevance, whether mild or severe.53-55
In the absence of technical errors, these and other similar
occurrences meet the deﬁnition of device-related adverse
events. The time frame for the development of these unto-
ward events is long; thus, safety analyses of ﬁlters should
span several years or more after implantation.
A common aberrance of ﬁlter deployment is “tilt” of
the ﬁlter. Tilt is quantiﬁed with measurement of the angle
of the device in relationship to the centerline of the vessel.
Whereas a threshold of 15 degrees has been used to deﬁne
signiﬁcant tilt,56 the angle is difﬁcult to measure absent
three-dimensional reformatted imaging. A single plain
radiograph is inadequate to gauge tilting, particularly if
the tilt occurs orthogonal to the plane of the ﬁlm. Multiple
plain radiographs will improve accuracy in deﬁning tilt, but
three-dimensional imaging with centerline determinations
should be considered if tilt is an important end point in
any study. Noting the relationship between tilt and inability
to retrieve a ﬁlter, tilt qualiﬁes as a device-related adverse
event in and of itself.57
Venous angioplasty and stenting. Venous angio-
plasty with stenting is associated with many of the same
adverse events that occur with arterial interventions. Target
lesion restenosis or thrombosis and, to a lesser extent, stent
fracture are common to both arterial and venous indica-
tions. Venous angioplasty and stenting, however, can also
be followed by pulmonary embolism. When pulmonary
embolism occurs after venous interventions, it should be
classiﬁed as device related or procedure related, depending
on the timing of the complication and the device under
study. For example, embolization of mural thrombus dur-
ing predilation of a venous occlusion before stent place-
ment would be considered to be procedure related with
respect to the stent. Without a stent in place to mark the
site of intervention, thrombosis after balloon angioplasty,
a device-related adverse event, can be more difﬁcult to
ascertain in a vein than in an artery. The variability in
anatomy with the common occurrence of duplicate, par-
allel veins is an issue speciﬁc to the venous system, partic-
ularly the femoral vein, which has been reported to be
duplicated in 10% or more of patients. Further, incomplete
venous thrombosis and recanalization complicate the
diagnosis of patency. Importantly, DVT remote from the
site of intervention and pulmonary embolism unrelated to
the venous intervention are not device-related adverse
events and would be procedure related only if they
occurred within 30 days of the intervention. Otherwise,
distant thromboembolic complications are more likely to
be related to the underlying disease rather than to the
device or to the procedure.o Iatrogenic migration during manipulation of guidewires and catheters
through the ﬁlter at the time of a subsequent unrelated procedure would
be neither device nor procedure related with respect to the ﬁlter.
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the length over which an intervention was performed
plus 5 mm in either direction. The use of target lesion rein-
tervention is not a good primary end point for measuring
the safety or efﬁcacy of venous angioplasty and stenting.
Reinterventions are subject to investigator discretion.
Even when the end point is limited to clinically driven rein-
terventions, the presence of collateral venous channels or
the absence of signiﬁcant symptoms after reocclusion ren-
ders an intervention-driven end point such as TLR less
meaningful, and it may underestimate the true failure rate
at the treated site. Rather, venography or another validated
imaging study should be used to quantify primary, primary-
assisted, and secondary venous patency after stenting,
similar to arterial interventions. Similar to arterial adverse
event reporting, percentage stenosis or percentage resteno-
sis requires knowledge of the normal diameter of the vessel
at the location in question. This is even more difﬁcult to
ascertain in veins than in arteries, particularly as a result
of venous dilation after thrombosis. A measure such as
minimum diameter may be more practical, similar to late
lumen loss in arteries. However, cross-sectional area or ma-
jor and minor axes may be more relevant end points to
gauge venous stenoses,58 noting the often elliptical cross-
sectional shape of many veins.59
Venous thrombolysis and mechanical thrombec-
tomy. Pharmacologic thrombolysis with ultrasound
enhancement or venous PMT is a commonly employed
modality for treatment of DVT. Adverse events related to
these devices include malfunction of the devices, embolism,
hemorrhagic complications, and recurrent thrombosis.60-62
Many of the guidelines in this document for the reporting
of adverse events that occur with arterial thrombolysis are
also relevant to venous thrombolysis. In particular, speci-
ﬁcation of the target segment attains great importance in
venous thrombolysis because treatment of proximal and
distal thrombus is not always a goal of therapy. Whereas the
use of combined modalities such as angioplasty and stent-
ing with pharmacologic thrombolysis can obscure the
assignability of an adverse event to the drug or to a device,
it is useful to assign relatedness of adverse events whenever
possible. It is also advantageous to assess patency and
adverse events after each staged intervention, reporting
these end points separately after thrombolysis, angioplasty,
and stenting. A Clinical Events Committee can play an
important role to apply an impartial and standardized
approach to adjudicating events that occur during and after
these complex treatment scenarios.AUTHOR CONTRIBUTIONS
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